A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.
Overview
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) is a phase 3 interventional study registered as NCT07391657 by AstraZeneca, with 508 participants planned, started 2026-02-23 and due to reach its primary completion in 2028-06-14. Interventions recorded: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib. Conditions listed: Relapsed Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Shares AZD0120, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study of Daratumumab
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple
Shares Carfilzomib, Bortezomib, Daratumumab, Dexamethasone.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.